Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study
Public ClinicalTrials.gov record NCT05781321. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Stereotactic Accelerated Radiotherapy in GlioblastomA (SAGA)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase II trial compares the effect of short course radiotherapy (RT) to standard course RT for the treatment of patients diagnosed with glioblastoma (GBM). The researchers want to learn whether the shorter course treatment is non-inferior (not worse than the standard of care), for patients with GBM. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Short course radiotherapy delivers higher doses of radiation over a shorter period of time and may kill more tumor cells and have fewer side effects.
Study identification
- NCT ID
- NCT05781321
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 170 participants
Conditions and interventions
Conditions
Interventions
- Accelerated Hypofractionated Radiation Therapy Radiation
- Computed Tomography Procedure
- Fluorodopa F 18 Drug
- Magnetic Resonance Imaging Procedure
- Positron Emission Tomography Procedure
- Quality-of-Life Assessment Other
- Questionnaire Administration Other
- Radiation Therapy Radiation
- Temozolomide Drug
- Biospecimen Collection Procedure
Radiation · Procedure · Drug + 1 more
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 22, 2023
- Primary completion
- Nov 29, 2026
- Completion
- Nov 29, 2028
- Last update posted
- Jul 29, 2026
2023 – 2028
United States locations
- U.S. sites
- 8
- U.S. states
- 4
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic in Arizona | Scottsdale | Arizona | 85259 | — |
| Mayo Clinic in Florida | Jacksonville | Florida | 32224-9980 | — |
| Mayo Clinic Health System in Albert Lea | Albert Lea | Minnesota | 56007 | — |
| Mayo Clinic Health Systems-Mankato | Mankato | Minnesota | 56001 | — |
| Mayo Clinic Radiation Therapy - Northfield | Northfield | Minnesota | 55057 | — |
| Mayo Clinic in Rochester | Rochester | Minnesota | 55905 | — |
| Mayo Clinic Health System-Eau Claire | Eau Claire | Wisconsin | 54701 | — |
| Mayo Clinic Health System-Franciscan Healthcare | La Crosse | Wisconsin | 54601 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05781321, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 29, 2026 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05781321 live on ClinicalTrials.gov.